A phase IB, multicenter, open-label dose escalation study tested the antitumoral effects of BYL719 (PI3K inhibitor) in combination with AUY922 (HSP90 inhibitor) in advanced or metastatic GC patients carrying the PIK3CA mutation or with HER2 amplification. Here, PIK3CD is linked to gastric cancer.